[Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].


In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with… (More)